Coprescription of Tamoxifen and Medications That Inhibit CYP2D6
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Evidence has emerged that the clinical benefit of tamoxifen is related to the functional status of the hepatic metabolizing enzyme cytochrome P450 2D6 (CYP2D6). CYP2D6 is the key enzyme responsible for the generation of the potent tamoxifen metabolite, endoxifen. Multiple studies have examined the relationship of CYP2D6 status to breast cancer outcomes in tamoxifen-treated women; the majority of studies demonstrated that women with impaired CYP2D6 metabolism have lower endoxifen concentrations and a greater risk of breast cancer recurrence. As a result, practitioners must be aware that some of the most commonly prescribed medications coadministered with tamoxifen interfere with CYP2D6 function, thereby reducing endoxifen concentrations and potentially increasing the risk of breast cancer recurrence. After reviewing the published data regarding tamoxifen metabolism and the evidence relating CYP2D6 status to breast cancer outcomes in tamoxifen-treated patients, we are providing a guide for the use of medications that inhibit CYP2D6 in patients administered tamoxifen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Going from evidence to recommendations
Guyatt, G. H., Oxman, A. D., Kunz, R., Falck-Ytter, Y., Vist, G. E., Liberati, A., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39493.646875.ae · Cited by 1,810
Loprinzi, C. L., Kugler, J. W., Sloan, J. A., Mailliard, J. A., LaVasseur, B. I., Barton, D. L., Novotny, P. J., Dakhil, S. R., Rodger, K., Rummans, T. A., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03403-6 · Cited by 737
Self-citationPreskorn, S. H. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199700321-00003 · Cited by 370 · cited 2×
“Their effects in regards to CYP2D6 inhibition are listed in Table 3 and are derived from in vitro and in vivo pharmacokinetic studies.(39,42,45-53) It is important to highlight buproprion and duloxetine, because these drugs exhibit in vitro inhibition close to that of fluoxetine and paroxetine.”
BackgroundDezentjé, V. O., van Blijderveen, N. J. C., Gelderblom, H., Putter, H., van Herk-Sukel, M. P. P., Casparie, M. K., Egberts, A. C. G., Nortier, J. W. R., & Guchelaar, H.-J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0894 · Cited by 163
Cited by
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz173 · Cited by 2,214
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rutgers, E., Zackrisson, S., & Cardoso, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv298 · Cited by 1,597
Cardoso, F., Fallowfield, L., Costa, A., Castiglione, M., & Senkus, E. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr372 · Cited by 596
Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities
Xu, X., Zhang, M., Xu, F., & Jiang, S. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01276-5 · Cited by 588
Prodrugs—from Serendipity to Rational Design
Huttunen, K. M., Raunio, H., & Rautio, J. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003459 · Cited by 505
Patel, H. K., & Bihani, T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.12.012 · Cited by 499
Cardoso, F., Harbeck, N., Fallowfield, L., Kyriakides, S., & Senkus, E. (2012) · Annals of Oncology · doi:10.1093/annonc/mds232 · Cited by 485
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Senkus, E., Kyriakides, S., Penault-Llorca, F., Poortmans, P., Thompson, A., Zackrisson, S., & Cardoso, F. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt284 · Cited by 479
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
Perry, J. R., Bélanger, K., Mason, W. P., Fulton, D., Kavan, P., Easaw, J., Shields, C., Kirby, S., Macdonald, D. R., Eisenstat, D. D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5520 · Cited by 384
Potentially Harmful Drug–Drug Interactions in the Elderly: A Review
Hines, L. E., & Murphy, J. E. (2011) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2011.10.004 · Cited by 272
Mürdter, T. E., Schroth, W., Bacchus-Gerybadze, L., Winter, S., Heinkele, G., Simon, W., Fasching, P. A., Fehm, T., Eichelbaum, M., Schwab, M., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.27 · Cited by 270
Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs
van Leeuwen, R. W. F., Brundel, D. H. S., Neef, C., van Gelder, T., Mathijssen, R. H. J., Burger, D. M., & Jansman, F. G. A. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.48 · Cited by 264
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Cardoso, F. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr371 · Cited by 256
Depression as a Risk Factor for Cancer: From Pathophysiological Advances to Treatment Implications
Currier, M. B., & Nemeroff, C. B. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-061212-171507 · Cited by 126
Metadata
- Authors
- Sideras, K., Ingle, J. N., Ames, M. M., Loprinzi, C. L., Mrazek, D. P., Black, J. L., Weinshilboum, R. M., Hawse, J. R., Spelsberg, T. C., & Goetz, M. P.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-06-01
- Volume
- 28
- Issue
- 16
- Pages
- 2768-2776
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1994401414
- Cited by
- 143
- References
- 4
- FWCI
- 21.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.